Gen9 Chief Legal Officer Jennifer A. Camacho Named One Of World’s Leading IP Strategists

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, today announced that Chief Legal Officer Jennifer A. Camacho has been named to Intellectual Asset Management (IAM) magazine’s IAM Strategy 300: The World’s Leading IP Strategists list, which recognizes senior legal executives with an established track record in the development and rollout of strategies that maximize the value of patent, copyright, trademark and other IP rights.

“As in previous years, we have dedicated significant editorial and research resources to ensuring we identify only world-class IP strategists, so we are confident that all those named in the IAM Strategy 300 2015 fully merit the recognition that they have received”

“Jennifer has been instrumental in leading the expansion and management of Gen9’s industry-leading patent estate, a cornerstone of our BioFab® technology platform for the high-throughput, high-fidelity manufacture of synthetic DNA,” said Chief Executive Officer Kevin Munnelly. “We congratulate Jennifer on this accomplishment and are excited about our continued development of novel technologies that will change the game in how life science research is performed.”

“As in previous years, we have dedicated significant editorial and research resources to ensuring we identify only world-class IP strategists, so we are confident that all those named in the IAM Strategy 300 2015 fully merit the recognition that they have received,” said IAM editor Joff Wild. “With intellectual property now central to the success of so many companies across the globe, we are delighted that this publication has become the recognized source of reference for those seeking to identify the world’s leading IP strategists. What’s more, we believe that the roles all those named in the IAM Strategy 300 play is only going to increase in importance over the coming years. We salute each and every one of them.”

The IAM Strategy 300 is available in printed format and online at http://www.IAM-media.com/strategy300.

About Gen9

Gen9 is the premier next-generation DNA synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, MA, and can be found online at http://www.gen9bio.com.

Gen9, GeneBit, GeneByte and BioFab are registered trademarks of Gen9, Inc.